OBJECTIVES: Recent studies have shown favourable early results with decellularized allografts (DAs) for right ventricular outflow tract reconstruction during the Ross procedure. However, mid-and long-term outcome data are still scarce. The objective of this study was to compare the durability of fresh DAs with standard cryopreserved allografts (SCAs) in patients undergoing the Ross procedure.
INTRODUCTION
In spite of the controversies surrounding the Ross procedure for aortic valve replacement, recent published series suggest that, in selected patients, it may be associated with improved long-term survival and better quality of life when compared with other types of valve substitutes [1] [2] [3] [4] [5] [6] [7] .
One of the most important disadvantages of the Ross procedure is the fact that it involves a double-valve replacement to treat patients with a single-valve disease [8] . Reconstruction of the right ventricular outflow tract (RVOT) is most commonly achieved with cryopreserved pulmonary allografts, which are prone to early stenosis in the first 2 years after implantation or progressive degenerative structural valve dysfunction in a later phase [9] . It has been estimated that after 20 years, almost 50% of patients subjected to a Ross procedure will either need a reintervention of the right-sided allograft or present with echocardiographic signs of significant structural valve dysfunction [2] .
Although the mechanisms responsible for tissue degeneration are multifactorial, immunological response against donor antigens present in cryopreserved allografts seems to play a major role [10, 11] . In response, several decellularization techniques have been recently proposed as an alternative to conventional cryopreservation. By removing all the cellular components while maintaining an intact tissue architecture, the resulting acellular †Presented at the 31st Annual Meeting of the European Association for CardioThoracic Surgery, Vienna, Austria, 7-10 October 2017. matrix is hypothesized to be immunologically inert and capable of being repopulated 'in vivo' after implantation and thus potentially more durable [12] [13] [14] .
Short-and mid-term results with decellularized allografts (DAs) have suggested potential benefits, especially in younger patients or in grafts with smaller diameters [15, 16] . Our group has extensive work both in the experimental setting and in clinical investigations involving tissue engineering techniques for processing human heart valves [12, [17] [18] [19] . Having more than a decade of experience with DAs for the RVOT reconstruction during the Ross procedure [20, 21] , we sought to compare the clinical and echocardiographic outcomes of fresh DAs versus standard cryopreserved allografts (SCA) in a propensity-matched cohort study.
MATERIALS AND METHODS

Study cohort
Between May 1995 and February 2017, 521 consecutive patients underwent a Ross procedure, which was performed by a single surgeon (F.D.A.d.C.) at Santa Casa de Curitiba and Instituto de Neurologia e Cardiologia de Curitiba, Paraná , Brazil. During this period, the type of allograft used to reconstruct RVOT has evolved from conventional cryopreserved, followed by cryopreserved valves that were subsequently decellularized with either deoxycholic acid or sodium dodecyl sulphate and most recently with fresh sodium dodecyl sulphate DAs. This study includes patients with either fresh DAs (Group DA, n = 200) or SCAs (Group SCA, n = 202). The remaining 119 patients were treated with allografts processed with the use of different techniques and were excluded from further analysis. The Ethics Committee of Pontifícia Universidade Cató lica do Paraná (PUCPR) approved the study.
Allografts
All allografts were of pulmonary origin and were obtained from the Pontifícia Universidade Cató lica do Paraná (PUCPR) MultiTissue Bank. The protocol for cryopreservation has been previously described [17, 18] .
For DA, fresh allografts were decellularized immediately after sterilization using a low concentration 0.1% sodium dodecyl sulphate solution in shakers at 37 C for 24 h and stored at 4 C for up to 90 days in phosphate-buffered solution. This method has been patented (Brazilian patent, PI0800603-2) and licensed to Tissue Regenix Ltd, York, UK.
Operative technique
Details of the operative technique have been previously described [21] . In brief, surgery was performed with extracorporeal circulation under moderate hypothermia (32 C); myocardial protection was accomplished with antegrade cold blood cardioplegia. The autograft was implanted with the total root replacement (n = 360) or the inclusion technique (n = 42). Nine cases in the DA group concerned reoperations due to failed RVOT allografts after a previous Ross procedure.
The RVOT reconstruction was performed in a consistent fashion, independent of the type of allograft implanted. Allografts were cut at the level of the pulmonary bifurcation, and the muscle band at the proximal end was trimmed leaving only a small 2-3-mm rim. The distal suture line was always performed with a running suture of 4-0 or 5-0 polypropylene and tied over the Hegar dilator to avoid a purse string effect. The proximal anastomosis was also performed with a running 4-0 polypropylene suture, either directly (n = 346) or using a proximal hood of bovine (n = 11) or decellularized human pericardium (n = 45).
Clinical and echocardiographic follow-up
Postoperative clinical and 2D echocardiographic assessment was scheduled at discharge, 6 and 12 months postoperatively and yearly thereafter. Maximum velocities across the RVOT allograft were obtained by continuous Doppler measurement, and pressure gradients were calculated by the modified Bernoulli equation. The degree of conduit regurgitation was estimated by the maximum length and area of the regurgitant jet at the level of the outflow tract [22] and graded as absent, trivial, mild, moderate or severe. Follow-up in the unmatched cohort was 90.1% complete.
Data collection
All follow-up and data collection were conducted prospectively. Outcome events were defined according to the reporting guidelines [23] . Allografts were considered dysfunctional if they developed > _severe regurgitation and/or a peak Doppler gradient of > _36 mmHg [24] . Outcome events included all-cause mortality, development of allograft dysfunction, reintervention, endocarditis and a composite outcome of allograft dysfunction, allograft reintervention and all-cause mortality.
Statistical analysis
Propensity score construction and analyses. As there were significant differences between the DA and SCA patients in most baseline characteristics (Table 1) , we performed both propensity score adjustment and propensity score matching [25, 26] . The propensity scores were constructed using a non-parsimonious multivariable logistic regression model with the treatment variable (DA vs SCA) as the dependent variable. Because of their statistical and/or clinical significance, all baseline characteristics listed in Table 1 were included as covariates in the propensity model [25, 27, 28] .
For propensity score-adjusted analyses in the unmatched cohort, both the propensity score and the treatment allocation variable (DA vs SCA) were entered into Cox proportional hazards models for allograft dysfunction, allograft reintervention, mortality and the composite outcomes of these 3 events.
Additionally, propensity score matching was conducted at a 1:1 ratio with the use of the nearest neighbour matching method, as there was evidence of inadequate propensity adjustment in the propensity score-adjusted analyses (the propensity score was statistically significant in the adjusted Cox regression model for allograft dysfunction) [28, 29] . A propensity score difference of 0.15 was used as a maximum caliper width for matching 2 patients.
Analyses of clinical data. Analyses of clinical data were performed using R (version 3.3.2, R Foundation for Statistical
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Computing, Vienna, Austria). Continuous data are presented as mean ± standard deviation or median (range), and comparison in the unmatched cohort was done using the unpaired t-test unless the data were not normally distributed (the KolmogorovSmirnov test); in these instances, the Mann-Whitney U-test was used for comparison. Categorical data are presented as proportions, and comparison in the unmatched cohort was done using the v 2 test. Comparison in the matched cohort was done using the paired sample t-test, McNemar's test or Wilcoxon signedrank test, where appropriate.
Actuarial freedom from events was estimated according to the Kaplan-Meier method, and the Tarone-Ware test was used for comparisons. Cox proportional hazards models were used for propensity-adjusted analyses, as described above. All tests were 2-sided, and statistical significance was inferred at a P-value <0.05.
Analyses of echocardiographic data. Analyses of echocardiographic data were performed using R (version 3.3.2, R Foundation for Statistical Computing, Vienna, Austria). Linear mixed-effects models were used to assess changes in peak Doppler allograft gradient over time while accounting for the correlation between repeated follow-up measurements in each patient. To allow for more flexibility in the specification of the patient-specific longitudinal trajectories, we utilized natural cubic splines with 2 internal knots placed at the corresponding percentiles of the follow-up times. Residual plots were used to validate the model's assumption, and when appropriate, transformations of the outcome variables were performed. Missing echocardiogram measurements were assumed to be missing at random [30, 31] .
RESULTS
Clinical outcome in the unmatched cohort
Baseline patient characteristics of the unmatched DA (mean followup = 3.4 ± 2.6 years) and SCA (mean follow-up = 12.6 ± 5.3 years) patients are listed in Table 1 . Operative details and outcome events in the unmatched cohort are listed in the Supplementary Material, Table S1 . Hazards of allograft dysfunction, reintervention, all-cause mortality and the composite outcomes of all 3 were comparable between DA and SCA, both before and after propensity adjustment in the unmatched cohort (Supplementary Material, Table S2 ). However, the propensity score variable was statistically significant in the regression model, which suggests inadequate adjustment for baseline differences. Adjusted for the treatment allocation variable (DA vs SCA), year of surgery was not associated with the hazards of allograft dysfunction (Cox regression, P = 0.215), allograft reintervention (P = 0.682), all-cause mortality (P = 0.399) or the composite outcomes of all 3 (P = 0.527) in the unmatched cohort.
Exploration of the propensity score distribution of the 2 treatment groups revealed a substantial overlap in propensity scores between the 2 groups (Supplementary Material, Fig. S1 ).
Clinical outcome in the matched cohort
One hundred and thirty DA patients (mean follow-up 4.2 ± 2.6 years) were propensity score matched with 130 SCA patients (mean follow-up 13.0 ± 4.5 years).
After propensity matching, there were no significant baseline differences between the 2 groups (Table 1) . There was an adequate covariate balance across the 2 groups, as absolute standardized mean differences were <10% for all measured covariates (Supplementary Material, Fig. S2 ).
Operative details and outcome events in the matched cohort are listed in Tables 2 and 3 . After matching, early mortality and 8-year actuarial survival were comparable between the 2 groups (P = 0.759) (Fig. 1) (Table 3 ).
In the matched cohort, there were 7 cases of DA dysfunction during a follow-up of 558 patient-years (1.25% per year) and 28 cases of SCA dysfunction during a total follow-up of 1699 patient-years (1.65% per year). All cases of allograft dysfunction concerned moderate-to-severe stenosis.
Actuarial analysis in the matched cohort revealed comparable freedom from allograft dysfunction at 8 years [DA = 86.7% 95% confidence interval (CI) 63.6-95.6; SCA = 87.3% 95% CI 80.1-92.0] (P = 0.183) (Fig. 2) .
There was 1 allograft reintervention in the DA group (0.18% per year) due to endocarditis and 8 in the SCA group (structural valve dysfunction = 6, endocarditis = 2; 0.47% per year). At 8 years, freedom from reintervention was comparable between the matched groups (DA 99.2%, 95% CI 94.3-99.9; SCA 97.6%, 95% CI 92.7-99.2, P = 0.642) (Fig. 3) .
Freedom from the composite outcome of allograft dysfunction, allograft reintervention and all-cause mortality at 8 years was comparable between the matched groups (DA 81.6%, 95% CI 62.4-91.6; SCA 82.9%, 95% CI 75.2-88.4) (Fig. 4) .
Echocardiographic outcome in the matched cohort
Overall, 1342 echocardiograms were available for analysis in the matched cohort (mean; 5.2 per patient). Longitudinal serial echocardiographic measurements (Fig. 5) revealed that in the 
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immediate postoperative period, peak RVOT gradients were comparable between DAs and SCAs (b = -0.696, P = 0.514). However, when looking at the progression rate of the gradient, there was a significantly lower rate of progression in DA compared with SCA when considering the first 0.5 years (b = -4.476, P = 0.028) and the first 3 years (b = -3.710, P = 0.041) postoperative. Progression rates were comparable from 3 years postoperative onwards (b = 0.887, P = 0.582). Although absolute gradients were lower in the DA group, this difference did not reach statistical significance as evidenced by the overlapping 95% CI bands (Fig. 5) . During this period, there was also a marked increase in allograft regurgitation grades over time, although there was no progression to severe insufficiency in any patient.
DISCUSSION
The concept of decellularized heart valve allografts was first introduced by O'Brien et al. [13] . Subsequently, several authors using different decellularization techniques have shown promising results in the experimental setting [12, 14] .
Preliminary single-centre reports have documented the shortterm safety of DAs for RVOT reconstruction, mainly in patients with congenital heart diseases [32] . However, mid-and long-term outcomes are still scarce, with most of the data being restricted to a few centres worldwide [15, 16] .
More recent studies have confirmed favourable results during the first decade and suggested an possible advantage in certain subsets of patients [15, 16] . Notwithstanding they have important limitations, as the diversity of patients and pathologies being treated makes a direct comparison problematic. Furthermore, different technologies employed to achieve complete decellularization may also have a significant impact on clinical outcomes [15, 16] . A strength of our study is that it comprises only Ross patients, where the allografts are placed uniformly in the orthotopic position and, thus, avoiding the influence of anatomical factors on conduit performance.
Our study shows that up to 8 years of follow-up, SCA and DA groups had comparable freedom from allograft dysfunction. However, serial echocardiographic measurements revealed significantly lower progression rates of allograft gradients in the DA group in the first 3 postoperative years, although absolute gradients remained comparable. Longer follow-up and larger series may reveal evidence of the hypothesized advantage of allograft decellularization. Our freedom from DA stenosis (peak gradient > _ 36 mmHg) of 87% at 8 years is encouraging. In the experience of Sarikouch et al. [16] with DAs in patients with a mean age of 15 years, the 10-year freedom from peak gradients of 25 mm Hg and 50 mmHg were 20% and 85%, respectively. Ruzmetov et al. [32] reported a 10-year freedom from DA dysfunction of 74%, with the majority involving a peak gradient > _ 40 mmHg [32] .
The need for valvular reinterventions should always be interpreted with caution as it is related not only to the degree of valvular dysfunction but also to institutional policies for reintervention [16] . In this series, freedom from reintervention was low and comparable among DAs. This finding is in line with expectations since reoperations on the right side are infrequently needed in the first decade after the Ross procedure, independent of conduit type [2, 4] .
A relevant finding of this study is the significantly lower progression rate of gradients during the first 3 years after implantation in DA when compared with SCA, as demonstrated by the longitudinal analysis of serial echocardiographic measurements. This is in accordance with the results of the Hannover group, where DAs tended to show lower gradients when compared with bovine jugular veins and cryopreserved allografts, although the difference in absolute gradient progression did not reach statistical significance up to 5-8 years of follow-up in their study either [15, 16] .
The favourable haemodynamic performance of DAs may, at least in part, be explained by the absence or a lesser degree of allograft shrinkage that is commonly seen after SCA implantation [9, 33] . An ongoing study at our institution with serial CT scans after the Ross procedure demonstrated not only larger diameters but also the absence of late calcification on the arterial wall of DA. It is hypothesized that by being less immunogenic, the acellular matrices are associated with a diminished inflammatory response and better healing characteristics that enables the conduit to maintain their original diameter after implantation [11, 14] .
This feature of DA may be relevant in certain circumstances, such as in younger patients and with the use of allografts with smaller diameters [15] . Our group has recently published promising results of DAs in children younger than 12 years with complex congenital heart diseases, where freedom from allograft stenosis was 85% at 10 years (34) .
Among the valve-related complications, infective endocarditis represents a life-threatening event. Similar to SCAs, DAs have shown a low incidence of infections at early and late follow-up, even in patients operated on during the acute phase of bacterial endocarditis. Awareness of this characteristic is important when choosing the most appropriate RVOT substitute, as other conduits have been previously described to be associated with an alarming incidence of late endocarditis [16] .
Strengths and limitations
In the absence of a randomized trial, this study employs propensity score matching to produce comparable study groups, which provides the unique opportunity for direct comparison between DA and SCA for RVOT reconstruction in a large cohort of patients undergoing the Ross procedure. Moreover, the large number of available echocardiograms and the powerful longitudinal data analysis techniques allowed us to analyse haemodynamic allograft function over time, in addition to clinical outcome. Furthermore, all patients in both groups were operated on by a single dedicated surgeon in a single centre, which greatly increases consistency and comparability.
This study has several limitations. As a consequence of the novelty of allograft decellularization, the follow-up duration of the DA group was insufficient to gain insight into long-term allograft function. There may still be other factors of influence on outcome that were not included in the propensity score. The year of surgery differed between the 2 groups and may have influenced the results, although our analyses showed no association between year of surgery and outcome.
